Compare LTC Properties Inc (LTC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs State Street SPDR S&P Biotech ETF — how do they compare? LTC Properties Inc trades at $38.12 (market cap $2.05B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: LTC Properties Inc pays a 5.98% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, LTC Properties Inc nearer its low. Which is the better fit depends on your goals.
| LTC | XBI | |
|---|---|---|
Market Cap | $2.05B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $42.81 | $164.28 |
52-Week Low | $33.98 | $86.92 |
Enterprise Value | $2.79B | — |
Dividend Yield | 5.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties (LTC) trades at $38.69, down 1.85% over 24 hours, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported Q2 2026 earnings that beat expectations, with EPS of $0.56 versus $0.48 expected, and continues aggressive SHOP portfolio expansion, with recent acquisitions totaling over $285 million year-to-date. Revenue grew to $262.85 million in 2025, and net income margin remains strong at 38.93%, though recent quarters show mixed earnings performance.
LTC presents a mixed outlook; strong fundamentals and dividend yield near 5.9% appeal to income investors, but bearish technicals and elevated debt levels pose risks. Analyst consensus is cautious with 59% hold ratings, reflecting concerns over execution amid rapid portfolio growth. Key catalysts include SHOP acquisition success and demographic tailwinds, while risks involve interest rate sensitivity and integration challenges.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
